|
JP3839667B2
(ja)
*
|
1998-06-08 |
2006-11-01 |
エフ．ホフマン−ラ ロシュ アーゲー |
慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
|
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
PL359169A1
(en)
|
2000-05-26 |
2004-08-23 |
Idenix (Cayman) Limited |
Methods and compositions for treating flaviviruses and pestiviruses
|
|
AU8353601A
(en)
*
|
2000-08-07 |
2002-02-18 |
Sciclone Pharmaceuticals Inc |
Treatment of hepatitis c with thymosin, interferon and ribavirin
|
|
US7208167B2
(en)
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
|
US7179791B2
(en)
|
2001-01-11 |
2007-02-20 |
Duke University |
Inhibiting GS-FDH to modulate NO bioactivity
|
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
KR20050035194A
(ko)
*
|
2002-06-28 |
2005-04-15 |
이데닉스 (케이만) 리미티드 |
플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
|
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
AU2003247084B9
(en)
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
|
AU2003298658A1
(en)
|
2002-11-15 |
2004-06-15 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
|
US7598373B2
(en)
|
2002-12-12 |
2009-10-06 |
Idenix Pharmaceuticals, Inc. |
Process for the production of 2-C-methyl-D-ribonolactone
|
|
MXPA05006865A
(es)
*
|
2002-12-23 |
2005-12-12 |
Idenix Cayman Ltd |
Proceso para la produccion de profarmacos 3'-nucleosidos.
|
|
RU2358979C2
(ru)
|
2003-05-30 |
2009-06-20 |
Фармассет, Инк. |
Модифицированные фторированные аналоги нуклеозида
|
|
US8615282B2
(en)
|
2004-07-13 |
2013-12-24 |
Dexcom, Inc. |
Analyte sensor
|
|
US20060040944A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
ES2725457T3
(es)
|
2004-09-14 |
2019-09-24 |
Gilead Pharmasset Llc |
Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
|
|
US7892827B2
(en)
|
2004-11-26 |
2011-02-22 |
Pieris Ag |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
RU2008109649A
(ru)
*
|
2005-08-15 |
2009-09-27 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В
|
|
US9201979B2
(en)
*
|
2005-09-14 |
2015-12-01 |
Millennial Media, Inc. |
Syndication of a behavioral profile associated with an availability condition using a monetization platform
|
|
US7781576B2
(en)
*
|
2005-12-23 |
2010-08-24 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
US8420051B2
(en)
|
2008-06-24 |
2013-04-16 |
Technische Universitaet Meunchen |
Muteins of hNGAL and related proteins with affinity for a given target
|
|
AU2009293493B2
(en)
*
|
2008-09-17 |
2014-09-18 |
Boehringer Ingelheim International Gmbh |
Combination of HCV NS3 protease inhibitor with interferon and ribavirin
|
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
|
MX2011006890A
(es)
|
2008-12-23 |
2011-07-20 |
Pharmasset Inc |
Analogos de nucleosidos.
|
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
|
JP2012526149A
(ja)
|
2009-05-08 |
2012-10-25 |
サイクローン・ファーマシューティカルズ・インコーポレイテッド |
ワクチン増強剤としてのαチモシンペプチド
|
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
BR112012002709A2
(pt)
|
2009-08-05 |
2019-04-30 |
Pieris Ag |
formulações de liberação controlada de muteínas de lipocalina
|
|
KR20120106942A
(ko)
|
2009-10-30 |
2012-09-27 |
베링거 인겔하임 인터내셔날 게엠베하 |
Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
|
|
BR112012013662B1
(pt)
|
2009-12-07 |
2022-08-02 |
Pieris Pharmaceuticals Gmbh |
Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
|
|
AP2012006535A0
(en)
|
2010-03-31 |
2012-10-31 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorous containing actives
|
|
AU2011263786B2
(en)
|
2010-06-08 |
2014-11-13 |
Astrazeneca Ab |
Tear lipocalin muteins binding IL-4 R alpha
|
|
AU2011290751B2
(en)
|
2010-08-16 |
2015-08-13 |
Pieris Ag |
Binding proteins for Hepcidin
|
|
CA2817779C
(en)
|
2010-11-15 |
2019-02-19 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
|
US9221885B2
(en)
|
2010-12-02 |
2015-12-29 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for CTLA-4
|
|
HRP20180237T4
(hr)
|
2011-09-16 |
2020-12-11 |
Gilead Pharmasset Llc |
Metode za liječenje hcv-a
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
EP3453400B1
(en)
|
2011-12-13 |
2021-01-20 |
Pieris Pharmaceuticals GmbH |
Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
US20140039923A1
(en)
*
|
2012-08-03 |
2014-02-06 |
AxelaCare Health Solutions, Inc. |
Computer program, method, and system for receiving and managing patient data gathered during patient treatments
|
|
EP2920202B1
(en)
|
2012-11-19 |
2018-08-29 |
Pieris Pharmaceuticals GmbH |
Novel specific-binding polypeptides and uses thereof
|
|
EP2950786B1
(en)
|
2013-01-31 |
2019-11-27 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
WO2014140210A1
(en)
|
2013-03-14 |
2014-09-18 |
Pieris Ag |
Novel binding proteins for pcsk9
|
|
EA201690473A1
(ru)
|
2013-08-27 |
2017-03-31 |
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи |
Комбинированный состав двух противовирусных соединений
|
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
EP3145945B1
(en)
|
2014-05-22 |
2020-07-15 |
Pieris Pharmaceuticals GmbH |
Novel specific-binding polypeptides and uses thereof
|
|
SG11201705278QA
(en)
|
2015-01-28 |
2017-07-28 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for angiogenesis
|
|
EP3259282A1
(en)
|
2015-02-18 |
2017-12-27 |
Sanofi |
Novel proteins specific for pyoverdine and pyochelin
|
|
PH12017501583B1
(en)
|
2015-05-04 |
2023-01-20 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for cd137
|
|
RU2727165C2
(ru)
|
2015-05-04 |
2020-07-21 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид с противораковой активностью
|
|
DK3298030T5
(en)
|
2015-05-18 |
2024-10-07 |
Pieris Pharmaceuticals Gmbh |
Anti-cancerfusionspolypeptid
|
|
EP3298029A1
(en)
|
2015-05-18 |
2018-03-28 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
|
EP3115371A1
(en)
|
2015-07-07 |
2017-01-11 |
Sanofi |
Fusion molecules
|
|
MX2018000447A
(es)
|
2015-07-15 |
2018-08-15 |
Pieris Pharmaceuticals Gmbh |
Novedosas proteinas especificas para lag-3.
|
|
US10703810B2
(en)
|
2015-11-30 |
2020-07-07 |
Pieris Australia Pty Ltd. |
Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
|
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
|
JP7225116B2
(ja)
|
2017-01-18 |
2023-02-20 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
|
|
RS64343B9
(sr)
|
2018-07-31 |
2023-11-30 |
Pieris Pharmaceuticals Gmbh |
Novi fuzioni protein specifičan za cd137 i pd-l1
|
|
JP7476219B2
(ja)
|
2019-02-26 |
2024-04-30 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
|
|
CA3177098A1
(en)
|
2020-06-05 |
2021-12-09 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1bb
|
|
AU2022253567A1
(en)
|
2021-04-08 |
2023-11-23 |
Pieris Pharmaceuticals Gmbh |
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
|
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
|
PE20251544A1
(es)
|
2022-09-21 |
2025-06-05 |
Seagen Inc |
Nueva proteina de fusion especifica para cd137 y cd228
|
|
WO2025175123A1
(en)
|
2024-02-16 |
2025-08-21 |
Seagen Inc. |
Methods of treating cancer using fusion proteins specific for cd137 and cd228
|